ArticleNeoplasia (New York, N.Y.)2007
Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy.
Article in Neoplasia (New York, N.Y.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- HSPB1 polymorphisms might be associated with radiation-induced damage risk in lung cancer patients treated with radiotherapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Pooled it
- Oxidative stress as a catalyst in prostate cancer progression: unraveling molecular mechanisms and exploring therapeutic interventions.Discover oncology · 2025Review
- Characterization of the Peroxisomal Proteome and Redox Balance in Human Prostate Cancer Cell Lines.Antioxidants (Basel, Switzerland) · 2024Article
- Gut microbiota metabolites, redox status, and the related regulatory effects of probiotics.Heliyon · 2023Review
- Article
- Apoptosis-inducing factor: a mitochondrial protein associated with metabolic diseases-a narrative review.Cardiovascular diagnosis and therapy · 2023Review
- Inaugurating a novel adjuvant therapy in urological cancers: Ferroptosis.Cancer pathogenesis and therapy · 2023Review
- The Interplay between Finasteride-Induced Androgen Imbalance, Endoplasmic Reticulum Stress, Oxidative Stress, and Liver Disorders in Paternal and Filial Generation.Biomedicines · 2022Review
- Drivers of Radioresistance in Prostate Cancer.Journal of clinical medicine · 2022Review
- Heat Shock Protein 27 Affects Myeloid Cell Activation and Interaction with Prostate Cancer Cells.Biomedicines · 2022Article
- Prostate cancer addiction to oxidative stress defines sensitivity to anti-tumor neutrophils.Clinical & experimental metastasis · 2022Article
- Cyanidin 3-O-arabinoside suppresses DHT-induced dermal papilla cell senescence by modulating p38-dependent ER-mitochondria contacts.Journal of biomedical science · 2022Article
- The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity.Current issues in molecular biology · 2022Article
- From kitchen to clinic: Pharmacotherapeutic potential of common spices in Indian cooking in age-related neurological disorders.Frontiers in pharmacology · 2022Review
- Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Xanthine Oxidase/Dehydrogenase Activity as a Source of Oxidative Stress in Prostate Cancer Tissue.Diagnostics (Basel, Switzerland) · 2020Article
- Molecular determinants of response to high-dose androgen therapy in prostate cancer.JCI insight · 2019Article
- Initial biological evaluations ofEJNMMI research · 2019Article
- High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation.Scientific reports · 2018Article
- Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer.Nature communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation therapy is a standard treatment for prostate cancer (PC). The postulated mechanism of action for radiation therapy is the generation of reactive oxygen species (ROS). Adjuvant androgen deprivation (AD) therapy has been shown to confer a survival advantage over radiation alone in high-risk localized PC. However, the mechanism of this interaction is unclear. We hypothesize that androgens modify the radioresponsiveness of PC through the regulation of cellular oxidative homeostasis. Using androgen receptor (AR)(+) 22rv1 and AR(-) PC3 human PC cell lines, we demonstrated that testosterone increased basal reactive oxygen species (bROS) levels, resulting in dose-dependent activation of phospho-p38 and pAKT, and increased expression of clusterin, catalase, and manganese superoxide dismutase. Similar data were obtained in three human PC xenografts; WISH-PC14, WISH-PC23, and CWR22, growing in testosterone-supplemented or castrated SCID mice. These effects were reversible through AD or through incubation with a reducing agent. Moreover, testosterone increased the activity of catalase, superoxide dismutases, and glutathione reductase. Consequently, AD significantly facilitated the response of AR(+) cells to oxidative stress challenge. Thus, testosterone induces a preset cellular adaptation to radiation through the generation of elevated bROS, which is modified by AD. These findings provide a rational for combined hormonal and radiation therapy for localized PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.